NEW YORK, Dec. 6 - Invitrogen on Thursday announced that it has increased from $400 million to $500 million its private offering of convertible subordinated notes due 2006.
Registering provides access to this and other free content.
Already have an account?Login Now.
In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.
The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.
A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.
Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.